Journal of cardiovascular medicine
-
J Cardiovasc Med (Hagerstown) · Mar 2015
Randomized Controlled Trial Multicenter StudyHigh-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention.
To evaluate the efficacy of high-dose atorvastatin on contrast-induced nephropathy (CIN) occurrence in patients with ST-elevation myocardial infarction undergoing primary angioplasty. ⋯ High-dose atorvastatin pretreatment does not seem to prevent CIN in patients receiving primary angioplasty. However, it has the potential to lower CIN in patients with renal insufficiency and in the elderly.